Canada markets open in 8 hours 11 minutes

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.59+0.03 (+0.40%)
At close: 04:00PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • M
    Mark
    late day action - quiet and flat before tomorrow earnings - positive sign, i'll take a 10x larger position today and see if my gut is correct.
  • O
    Ozanou Muldusu
    filsuvez accepted
  • H
    Heros
    Amryt Pharma Announces FDA Granted Orphan Drug Designation For Octreotide For The Treatment Of Carcinoid Syndrome
  • Y
    Yonatan
    Hi all ,
    I wanted to share my calculation and ask for advice or correction from more experienced people here.
    As for what I understand $CHMA was purchased by $AMYT based on the announcement today.
    Every CHMA stock will be converted to AMYT stock at a ration of 1:0.396 , hence every 5 CHMA stock will grant their owner 2 AMYT stocks.
    this process based on my understanding diluted AMYT stock price for the short term. hopefully the purchase will yield profits in the future but this is a gamble for the long run .
    for now there are 41.79M outstanding CHMA shares , that by ration of 0.396 will become 16.54M AYMT share.
    currently, AYMT has 35.88M shares outstanding , and in the end of the purchase will have 52.42M shares.
    35.88/52.42 = 0.6844
    hence the AYMT stock should be diluted around 32% for the short term.
    taking its value to be 13.5 based on last 3 months (pretty high but lets be optimistic) , the new value after dilution should be :
    13.5*0.68= 9.18$ a share.
    assuming the real value of AYMT did not change , not by assets or anything else.
    this is only math wise.

    is it right by far ?

    other considerations :
    a) CLAIM (cons) - The value might be lower than 9.18$ for the short term :
    As CHMA still not FDA approved, more money will need to be spent before any profit will come (at least 1-2 years) , hence the expenses grow at start which will drive the share price down at next reports.

    b) CLAIM (pro) - the price will be higher than 9.18$ , my estimate 10-11$ a share as the optimism is around, purchase is considered a good thing, to grow the business.... and this will translate into share price regardless of book value or with taking into account future revenues, at least at the short term.

    I cant see any justification not to sell my AMYT share now and buy them back again in 3 months time.

    any advice , correction to the above ?
    pls correct my logic if you think otherwise.

    thanks.
  • K
    Kaan
    This was my best buy. This is still my best buy. AND it's gonna get higher i hope
  • 박
    Tell me if there's anyone who bought it. I'm bored
  • s
    steve
    Price drop is down to de-listing form the UK AIM market. This will cause a number of forced sales. Understand why, but could it not have been better handled?
  • F
    Faris
    PDUFA date under priority review November 30, 2021
  • C
    Chuck
    AMYT is raising revenue guidance for FY 2021 from prior guidance of between $210M - $215M to a range of $220M - $225M.
  • R
    Rustle Feathers
    average price target is $35. why are we still trading in 10-11 range?
  • 박
    fly high
  • C
    Chuck
    Buy rating with $45 price target.
  • y
    yaniv
    This is a holding company that has acquired a number of wonderful companies that are each worthwhile and have potential, I do not see the realization of synergy in products and certainly not in value
  • K
    Kaan
    We're running to EMA CHMP and PDUFA dates. Looking really good.
  • R
    Rabah
    Nobody Know this little baby ?!
  • P
    Peter
    The company should be generating cash from operations, the 'merger' ie acquisition should have been a cash and debt purchase. The low number of shares outstanding is one of the main attractions of a company like this, now that is screwed up. The problem is that it is always jam tomorrow you are dealing with a company that should be generating cash NOW but its jam tomorrow and we acquire a pipeline company and that is a jam tomorrow proposition also. Reminds me of the sign in the bar that says Free Drinks Tomorrow.
  • b
    bloodsport
    (CYTH) MCap $28 m--BIG Orphan Drug in Phase 3 & a Phase 2 Alzheimer Program = Sleeping GIANT with 10+ bagger opp
    https://cyclotherapeutics.com/wp-content/uploads/2021/12/CYTHPipe12.13B.png

    #
  • Y
    Yahoo Finance Insights
    Amryt Pharma is up 7.35% to 7.89
  • K
    Kaan
    ER is incoming.. what's your guess ?